相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
MRD Assessment in Multiple Myeloma: Progress and Challenges
Luca Bertamini et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)
Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma
Wenmin Han et al.
HEMATOLOGY (2021)
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
High-risk cytogenetics in multiple myeloma: Further scrutiny of deletions within the IGH gene region enhances risk stratification
Scott C. Smith et al.
GENES CHROMOSOMES & CANCER (2020)
High Oct4 expression: implications in the pathogenesis of neuroblastic tumours
Ezequiel Monferrer et al.
BMC CANCER (2019)
Selective isolation and noninvasive analysis of circulating cancer stem cells through Raman imaging
Hyeon-Yeol Cho et al.
BIOSENSORS & BIOELECTRONICS (2018)
Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics
Joyce W. Kamande et al.
INTEGRATIVE BIOLOGY (2018)
Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders
Brad Foulk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma
Ola Landgren et al.
CLINICAL CANCER RESEARCH (2016)
New criteria for response assessment: role of minimal residual disease in multiple myeloma
Bruno Paiva et al.
BLOOD (2015)
Quantification of clonal circulating plasma cells in relapsed multiple myeloma
Wilson I. Gonsalves et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
IMWG consensus on risk stratification in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2014)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
S. K. Kumar et al.
LEUKEMIA (2012)
Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma
Valdas Peceliunas et al.
LEUKEMIA & LYMPHOMA (2012)
The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
K. Vandyke et al.
BLOOD CANCER JOURNAL (2011)
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
Laurence Lode et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Unique biomechanical interactions between myeloma cells and bone marrow stroma cells
Yongdong Feng et al.
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY (2010)
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Sunitha Nagrath et al.
NATURE (2007)
Immunologic basis for the rare occurrence of true nonsecretory plasma cell dyscrasias
C Decourt et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)